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Context:	  Endothelial	  cell	  (EC)	  tumors	  are	  the	  most	  common	  soft-­‐tissue	  tumors	  in	  infants	  and	  children.	  	  Their	  spontaneity	  in	  regional	  development	  and	  developmental	  capacity	  can	  have	  detrimental	  effects	  on	   their	  hosts.	   	   	  The	  EC	  tumors	  occur	   in	  1-­‐2%	  of	  children,	  worldwide	  (Gordillo	   and	   Sen,	   2009).	   	   This	   occurrence	   is	  markedly	   higher	   in	   Caucasian	   children,	   as	  nearly	   10%	   of	   Caucasian	   children	  will	   develop	   EC	   tumors	   compared	   to	   other	   ethnicities	  (Gordillo	   and	   Sen,	   2009).	   	   Although	   these	  EC	   tumors	   are	   classified	   as	   benign,	   the	   body’s	  natural	  immune	  response	  to	  the	  tumors	  can	  lead	  them	  to	  their	  classification	  as	  Kaposiform	  Hemangioendotheliomas	   (KHE).	   	   	   This	   KHE	   is	   an	   intermediate	   grade	  malignancy,	   due	   to	  their	  potential	  to	  develop	  Kassabach-­‐Merritt	  phenomenon	  (Gordillo	  and	  Sen,	  2009).	  	  As	  the	  immune	  system	  responds	  with	  inflammation	  in	  the	  tumor	  region	  and	  increased	  blood	  flow	  to	  the	  tumor,	  the	  effective	  response	  is	  the	  sequestering	  of	  blood	  and	  platelets	  in	  the	  tumor.	  	  Without	   resolution,	   these	   features	   then	   lead	   to	   anemia,	   heart	   failure,	   and	   excessive	  bleeding	  (Gordillo	  and	  Sen,	  2009).	  	  KHE	  tumors	  with	  Kassabach-­‐Merritt	  phenomenon	  have	  a	  mortality	   rate	   of	   30%	   (Fernandez	   et	   al.,	   2009).	   	   EC	   tumors	   also	   embody	   spontaneous	  development	  in	  regions	  close	  to	  vital	  structures,	  and	  when	  paired	  with	  Kassabach-­‐Merritt	  phenomenon,	  these	  tumors	  then	  become	  highly	  malignant.	  	  For	  example,	  if	  a	  tumor	  forms	  in	  any	  proximity	  to	  an	  infant’s	  eye,	  the	  tumor	  would	  impair	  visual	  development,	  as	  a	  large	  red	  bulge	  of	  tumor	  flesh	  would	  slowly	  encroach	  into	  the	  infants’	  permanent	  visual	  field.	  	  In	  the	   same	   way,	   any	   tumor	   near	   the	   nasal	   cavity,	   the	   ears,	   mouth,	   or	   throat	   could	   cause	  improper	   development	   or	   even	   impede	   these	   structures	   entirely,	   causing	  mortality	   (see	  Fig.	  1).	  	  These	  specific	  tumors	  in	  humans	  are	  called	  Hemangioendotheliomas	  which	  will	  be	  abbreviated	  as	  HE	  for	  the	  continuation.	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Figure	   1	   	   	   	   Four-­‐month-­‐old	   child	  with	   a	   hemangioma	   threatening	   the	   child’s	   airway	   accessibility,	   thus	  requiring	  aggressive	  treatment	  The	  most	   common	   form	  of	   treatment	   for	   smaller,	   low-­‐grade	  HE	   tumors	   is	   termed	  “benign	  neglect,”	   as	  most	  HE	   tumors	  will	   resolve	   themselves	  within	   their	   lifespan	  of	   5-­‐9	  years.	   	  However,	   for	   those	   patients	  with	   life-­‐threatening	   tumors	   that	   interfere	  with	   vital	  anatomical	  structures	  (Fig.	  1),	  aggressive	  treatment	  is	  necessary.	  	  In	  these	  cases,	  treatment	  requires	  potent	  pharmacologic	  agents.	   	  Physicians	  currently	  prescribe	  high	  dose	  steroids	  (Gordillo	  and	  Sen,	  2009).	   	   Surgical	   excision	   is	  another	   form	  of	   treatment,	  however	   is	  not	  widely	  used	  because	  of	   the	  nature	   and	   scope	  of	   these	   tumors.	   	   Surgical	   excision	   is	   not	   a	  viable	   option	   when	   the	   HE	   tumor	   is	   in	   close	   proximity	   to	   vital	   structures	   because	   of	  potential	  injury	  to	  the	  structures	  themselves	  (Gordillo	  and	  Sen,	  2009).	  	  In	  the	  cases	  where	  tumors	   do	   not	   threaten	   vital	   structures,	   though,	   their	   sheer	   size	   risk	   a	   life-­‐threatening	  hemorrhage,	  negating	  the	  viability	  of	  surgery	  in	  most	  cases	  (Gordillo	  and	  Sen,	  2009).	  In	  the	  few	  cases	  where	  surgical	  excision	   is	  a	  possibility,	  residual	  scaring	  and	  physical	  defects	  of	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the	   invasive	   surgery	   are	   excessive	   and	  permanent	   (Gordillo	   and	   Sen,	   2009).	   	   Even	   if	   the	  tumor	  is	  left	  to	  resolve	  itself	  via	  tactics	  of	  benign	  neglect,	  research	  shows	  that	  50%	  of	  those	  children	   are	   left	   with	   a	   residual	   deformity	   requiring	   reconstructive	   plastic	   surgery	  (Mulliken,	  1997).	  Current	  treatment	  options	  include	  high	  dose	  steroids,	  interferon-­‐α,	  and	  propranolol	  (Gordillo	  and	  Sen,	  2009).	  	  These	  drugs	  not	  only	  lack	  a	  clearly	  defined	  molecular	  mechanism	  of	  action	  in	  the	  HE	  tumor	  cells,	  but	  also	  pose	  life-­‐threatening	  toxicity	  when	  used	  over	  the	  course	  of	  several	  months.	  	  This	  is	  a	  grave	  danger.	  	  The	  list	  of	  complications	  associated	  with	  the	  use	  of	   these	  drugs	   include:	   femur	   fractures,	   gastric	  ulcers,	   life-­‐threatening	   infections,	  hypotension,	   hypoglycemia,	   respiratory	   distress,	   and	   spastic	   diplegia	   (Gordillo	   and	   Sen,	  2009).	  	  	  It	   is	   necessary	   to	   develop	   a	   nutraceutical	   therapy	   that	   provides	   a	   non-­‐invasive	  alternative	  to	  the	  current	  methods	  of	  HE	  tumor	  care.	  	  This	  treatment	  should	  account	  for	  a	  mechanism	  of	  HE	  tumor	  proliferation.	  	  
HE	  Tumor	  Model	  	  	  	   Progress	  has	  been	  made	  in	  mapping	  the	  mechanism	  of	  HE	  tumor	  proliferation	  since	  Hoak	  et	  al.	  established	  and	  validated	  an	  endothelial	  cell	  line	  called	  Hemangioendothelioma	  (EOMA).	  	  EOMA	  can	  form	  KHE	  in	  the	  129	  P/3	  mouse,	  effectively	  modeling	  the	  human	  form	  of	   this	   tumor.	   	  When	   these	  mice	  are	  subcutaneously	   injected	  with	  EOMA	  cells,	   they	   form	  KHE	  with	  100%	  efficiency	  (Gordillo	  et	  al.,	  2004).	  	  Through	  the	  process	  of	  angiogenesis,	  the	  injected	   EOMA	   cells	   create	   blood-­‐sequestering	   tumors	   via	   connections	   with	   the	   host	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vasculature.	   	   These	   mice	   with	   KHE	   also	   develop	   Kassabach-­‐Merritt	   phenomenon.	   This	  model	   has	   been	   used	   by	   many	   other	   investigators	   to	   test	   the	   effectiveness	   of	   anti-­‐angiogenic	   compounds	   (Albini	   et	   al.,	   2001;	   Lannutti	   et	   al.,	   1997;	   O‘Reilly	   et	   al.,	   1995;	  Taraboletti	  et	  al.,	  1995;	  Wang	  et	  al.,	  1999).	  	  With	  this	  EOMA	  model,	  significant	  progress	  has	  been	  made	  in	  mapping	  tumor	  proliferation,	  leading	  to	  treatment	  strategies.	  
.	  
Molecular	  Mechanisms	  Involving	  Oxidant	  Production	  
	   One	   clear	   component	   of	  HE	   tumors	   is	   severe	   inflammation.	   	   This	   inflammation	   is	  triggered	   by	   reactive	   oxygen	   species	   (Roy	   et	   al.,	   2008).	   	   As	  NADPH	  oxidase	   is	   the	  major	  source	  of	  reactive	  oxygen	  species	  in	  endothelial	  cells,	  its	  activity	  is	  recognized	  as	  regulating	  cell	  signaling	  for	  the	  observed	  inflammation	  (Roy	  et	  al.,	  2008),	  making	  it	  a	  logical	  target	  for	  mediating	  hemangioma	  formation.	  	   NADPH	   oxidase	   is	   an	   enzyme	   with	   a	   catalytic	   core	   containing	   gp91.	   	   When	   this	  enzyme	  performs	  a	   single	  electron	   transfer,	   converting	   ingested	  molecular	  oxygen	   to	   the	  superoxide	  ion,	  the	  catalytic	  gp91	  component	  facilitates	  this	  electron	  transfer.	  	  In	  humans,	  
gp91	   takes	   form	   in	   7	   different	   homologs,	   while	   the	   mouse	   genome	   contains	   only	   6	  homologs.	   	  The	  nox-­‐2	  and	  nox-­‐4	  homologs	  are	  of	  importance	  in	  both	  models	  because	  they	  are	  the	  genes	  found	  in	  endothelial	  cells.	  	  When	  EOMA	  cells	  were	  screened	  by	  PCR	  for	  all	  6	  homologs	  of	  gp91,	  only	  NOX-­‐4	  was	  present.	  	  With	  this	  finding,	  NOX-­‐4	  became	  the	  primary	  target	   in	   the	   tumor	  mechanism.	   	   In	   further	   progress,	   NOX-­‐4	   was	   screened	   against	   non-­‐tumor	   forming	   transformed	   murine	   aortic	   endothelial	   (MAE)	   cells.	   	   Tests	   showed	   the	  presence	  of	  NOX-­‐4	  in	  quantity	  69-­‐fold	  greater	  than	  what	  was	  detected	  in	  the	  MAE	  cell	  line	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(Gordillo,	   et	   al.,	   2010).	   	   Currently	  unpublished	  data	   from	  Dr.	  Gordillo’s	   laboratory	   shows	  similar	  trends	  of	  high	  expression	  of	  NOX-­‐4	  in	  human	  hemangioma	  samples	  as	  well.	  	  These	  data	  are	   important	   in	  two	  ways:	   	   they	  verify	   that	   the	  mouse	  model	  accurately	  represents	  the	   human	   condition	   of	   hemangioma,	   and	   that	   high	   levels	   of	   NOX-­‐4	   expression	   occur	   in	  hemangioma	  tumors.	  	   When	  NOX-­‐4	  was	   silenced	   in	  EOMA	   cells,	   the	   cells	   experienced	   a	   loss	   of	   function.	  	  The	   knockdown	   of	  NOX-­‐4	   resulted	   in	   decreased	   cell	   proliferation	   in	  vitro	   and	   decreased	  tumor	  size	  in	  vivo.	  	  The	  biologically	  active	  form	  of	  oxidative	  stress	  produced	  by	  NOX-­‐4	  was	  also	   revealed	   as	   hydrogen	   peroxide	   (H2O2),	   produced	   through	   the	   dismutation	   of	  superoxide	   through	   metabolic	   processes	   (Gordillo,	   et	   al.,	   2010).	   	   The	   final	   investigation	  with	   NOX-­‐4	   was	   live	   cell	   imaging,	   which	   lead	   to	   the	   discovery	   that	   hydrogen	   peroxide	  formation	   occurs	   in	   the	   nucleus	   of	   these	   tumor	   cells,	   indicating	   that	   NOX-­‐4	   aggregates	  within	  the	  nuclear	  membrane	  (Gordillo,	  et	  al.,	  2010).	  	   The	   excess	   hydrogen	   peroxide	   found	   specifically	   in	   the	   nucleus	   makes	   DNA	   the	  primary	   target	   for	   oxidative	   modifications.	   	   As	   a	   relevant	   biomarker,	   oxidized	   DNA	  accumulation	  was	  found	  in	  the	  urine	  of	  mice	  harboring	  HE	  tumors	  (Gordillo,	  et	  al.,	  2010).	  	  Thus,	  NOX-­‐4	  activity	  may	  play	  a	  role	  in	  tumor	  promotion	  as	  it	  may	  serve	  as	  the	  main	  source	  of	  oxidative	  stress.	  	   Global	   research	   in	   solid	   tumor	   growth	   discovered	   the	   expression	   of	   many	  transcription	   factors	   that	   are	   activated	   by	   oxidative	   stress,	   resulting	   in	   cell	   proliferation	  and	   tumor	   promotion.	   	   The	   transcription	   factors	   AP-­‐1	   (activator	   protein	   1)	   and	   NF-­‐kB	  (Nuclear	  factor	  of	  kappa-­‐light-­‐chain-­‐enhancer	  of	  activated	  B	  cells)	  are	  redox	  sensitive	  and	  therefore	   inducible	   by	   hydrogen	   peroxide	   (Sen	   and	   Packer,	   1996)	   derived	   from	   NOX-­‐4.	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One	   of	   the	   downstream	   targets	   for	   these	   transcription	   factors	   is	   MCP-­‐1	   (Monocyte	  Chemoattractant	   Protein	   1).	   	  MCP-­‐1	   is	   a	  member	   of	   the	   chemokine	   family	   of	   proteins,	   a	  grouping	   of	   chemoattractant	   cytokines.	   	   This	   protein	   plays	   a	   major	   role	   in	   selectively	  recruiting	  macrophages	  and	  regulates	  the	  migration	  and	  infiltration	  of	  these	  macrophages	  (Deshmane	  2009).	  	  Both	  NF-­‐kB	  and	  AP-­‐1	  have	  been	  shown	  to	  bind	  to	  the	  MCP-­‐1	  promoter	  in	  endothelial	  cells	  (Martin	  et	  al.,	  1997).	  	   In	  my	  work	   in	  Dr.	  Gordillo’s	   lab,	   this	   is	   the	   extent	   of	   our	  perception	  of	   the	   tumor	  mechanism	   off	   of	   which	   this	   thesis	   is	   based.	   	   The	   findings	   in	   this	   mechanism	   provide	  context	  for	  the	  development	  of	  a	  nutraceutical	  treatment	  for	  hemangiomas,	  which	  is	  where	  my	  work	  in	  the	  research	  lab	  has	  honed	  in.	  	  Clearly,	  though,	  there	  are	  many	  more	  routes	  of	  experimentation	  that	  need	  to	  be	  investigated	  to	  complete	  the	  mapping	  of	  the	  hemangioma	  tumor	  mechanism.	  	  
A	   Treatment	   Against	   Tumorigenesis:	   	   Antioxidants	   from	  
Berries	  
	   Since	  redox	  sensitive	  transcription	  factors	  are	  clear	  components	  of	  cell	  proliferation	  in	  the	  EOMA	  model,	  naturally-­‐occurring	  antioxidants	  could	  be	  the	  answer	  to	  reducing	  the	  high	  oxidative	  stress	  found	  in	  the	  HE	  tumor.	  	  In	  this	  experiment,	  antioxidants	  will	  be	  tested	  via	   direct	   topical	   application	   to	   the	   tumors.	   	   Antioxidants	   are	   expected	   to	   eliminate	   the	  oxidative	   stress	   within	   the	   tumor,	   thereby	   preventing	   activation	   of	   transcription	   factors	  like	  NF-­‐kB	  and	  AP-­‐1.	   	  As	  a	   result,	   the	  MCP-­‐1	   gene	  will	   remain	   inactive.	   	  Additionally,	   the	  elimination	  of	  reactive	  oxygen	  species	  in	  the	  cell	  nucleus	  will	  create	  an	  environment	  where	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the	   cell	   will	   be	   able	   to	   maintain	   its	   intact	   DNA	   with	   greater	   efficiency,	   promoting	   the	  maintenance	  of	  healthy	  cells.	  Berry	  extracts—most	  specifically	  blueberry	  extracts—were	  selected	  as	  a	  possibility	  for	   therapeutic	   intervention	   because	   their	   high	   oxygen	   radical	   absorbance	   capacities	  (Haytowitz,	  et	  al.	  2010,	  Gordillo,	  2009)	  enable	  them	  to	  quench	  free	  radicals	  created	  in	  the	  nucleus.	   	   These	   extracts	   are	   also	   rich	   in	   anthocyanins,	  which	   are	   antiangiogenic	   and	   can	  inhibit	   AP-­‐1	   stimulated	   neoplastic	   transformation	   (Roy	   et	   al.,	   2002).	   	   This	   potential	  antioxidant	   therapy	   appears	   to	   have	   properties	   that	   address	   significant	   promoters	   of	  endothelial	  cell	  tumor	  growth.	  	  A	  proprietary	  blend	  of	  berry	  extracts	  (PediaBerry™)	  will	  be	  tested	  in	  the	  EOMA	  cell	  model	  in	  vitro.	  Berry	  extracts	  represent	  a	  viable	  therapeutic	  approach	  that	  could	  be	  available	  to	  all	  children	  with	  endothelial	  cell	  tumors.	   	  It	  is	  critical	  to	  study	  the	  topical	  application	  of	  berry	  extracts	   in	   reducing	   the	   oxidative	   stress	   present	   in	   HE	   tumor	   cells	   in	   order	   to	   create	   a	  nutraceutical	  and	  non-­‐invasive	  therapy	  option	  for	  patients	  with	  HE	  tumors.	  	  
Relevant	  Biomarkers	  in	  Tumor	  Proliferation	  
Besides	  techniques	   in	  recording	   lifespan	  rates	  and	  volumetric	  measurement	  of	  the	  tumors,	   various	   protein	   biomarkers	   exist	   in	   relation	   to	   hemangioma	   research	   and	   are	  important	   to	   this	   study.	   	   Collagen-­‐1	   is	   a	   fibrous	   protein	   that	   supports	   tissue	   structure,	  among	  many	  other	  roles.	  	  Collagen-­‐1	  is	  a	  protein	  chosen	  as	  a	  relevant	  biomarker	  of	  tumor	  proliferation	  in	  this	  study	  because	  of	  its	  previously	  established	  role	  in	  tumor	  research.	  	  One	  study	  found	  that	  the	  presence	  of	  Collagen-­‐1	  enhanced	  tumor	  cell	  proliferation	  (Ki	  2014).	  	  In	  another	  study,	  Collagen-­‐1	  was	  found	  to	  upregulate	  the	  expression	  of	  MT1-­‐MMP,	  a	  protein	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which	  induces	  the	  metastasis	  of	  disease	  (Ki	  2014).	  	  Adding	  to	  this,	  research	  has	  also	  shown	  that	  regions	  of	  tissue	  adjacent	  to	  benign	  tumors	  reveal	  high	  levels	  of	  collagen-­‐1	  deposition.	  	  Research	  has	  linked	  this	  finding	  to	  a	  greater	  flux	  in	  macromolecule	  transport	  to	  tumor	  cells	  (Kakkad	   2013),	   increasing	   tumor	   proliferation.	   	   When	   antifibrotic	   drugs	   successfully	  treated	   leiomyomas,	   benign	   smoothe	   muscle	   neoplasms,	   this	   research	   indicated	   that	  Collagen-­‐1	   plays	   a	   role	   in	   tumor	  maintenance	   as	   well	   (Islam	   2014).	   	   Using	   these	   cases,	  Collagen-­‐1	   serves	   as	   a	   biomarker	   fit	   for	   determining	   the	   effects	   of	   PediaBerry™	   on	   HE	  tumor	  proliferation.	  Ki-­‐67	   is	   another	   biomarker	   that	   can	   provide	   clear,	   significant	   insight	   in	   the	   cell	  proliferation	  taking	  place	  in	  this	  study.	   	  Expression	  of	  Ki-­‐67	  protein	  is	  associated	  directly	  with	   cell	   proliferation	   (Scholzen	   2000).	   	   During	   all	   active	   phases	   of	   the	   cell	   cycle	   Ki-­‐67	  protein	  is	  present,	  yet	  is	  absent	  from	  resting	  cells	  (Scholzen	  2000).	  	  The	  expression	  of	  Ki-­‐67	  makes	   it	   an	   excellent	   maker	   for	   determining	   cell	   proliferation.	   	   Scholzen	   provides	  numerous	   references	   to	   reputable	   studies	   that	   have	   used	   Ki-­‐67	   as	   a	   cell	   proliferation	  protein	  biomarker.	  	  The	  relevance	  of	  Ki-­‐67	  to	  other	  studies	  was	  carried	  over	  into	  this	  study.	  F4/80	   is	   the	   final	   biomarker	   relevant	   to	   this	   study.	   	   Reverting	   back	   to	   the	  mechanism	   which	   discovered	   that	   MCP-­‐1	   is	   a	   downstream	   target	   of	   the	   redox-­‐induced	  transcription	  factors,	  MCP-­‐1	  is	  known	  to	  be	  responsible	  for	  recruiting	  macrophages	  to	  sites	  of	  disease	  and	  inflammation,	  facilitating	  angiogenesis	  (Atalay	  et.	  al	  2003).	   	  This	  finding	  in	  macrophage	   activity	   in	   tumor	   sites	   provides	   another	   relevant	   biomarker	   into	   the	  angiogenic	   processes	   in	   hemangioma.	   	   F4/80	   is	   a	   well-­‐characterized	   and	   extensively	  referenced	   macrophage	   marker	   (Austyn	   and	   Gordon	   1981).	   	   In	   addition	   to	   recognizing	  kupffer	   cells,	  Langerhans	  cells,	  peritoneal	  macrophages,	   and	  various	  others,	  F4/80	  stains	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microglia	  as	  well	  (Lawson	  et	  al.	  1990).	  	  Research	  has	  shown	  significant	  adhesive	  properties	  of	   the	   anti-­‐F4/80	   antibody	   in	   connective	   tissue,	   which	   provides	   support	   for	   its	  implementation	  in	  this	  experiment.	  	  Research	  Question:	  	   Does	   the	   topical	   application	   of	   PediaBerry™	   suppress	   hemangioma	   tumor	   growth	  and	  promote	  longer	  lifespans	  of	  mice	  with	  hemangioma	  tumors?	  	  	  Hypothesis:	  	   My	   hypothesis	   was	   that	   daily,	   topical	   application	   of	   PediaBerry™	   ointment	   to	  induced	  murine	  HE	  tumors	  would	  significantly	  reduce	  the	  size	  of	  tumors	  and	  significantly	  increase	  the	  lifespans	  of	  the	  mice	  affected	  with	  the	  tumor.	  	  
Methods:	  
Animals:	  	  	  129	   P/3	   female	   mice	   (n	   =	   15)	   at	   4	   weeks	   of	   age	   were	   obtained	   from	   Jackson	  Laboratories	  and	  allowed	  7	  days	  of	  acclimation	  prior	   to	   treatment.	   	  Mice	  were	  housed	   in	  The	  Dorothy	  M.	  Davis	  Heart	   and	  Lung	  Research	   Institute,	   an	  Association	   for	  Assessment	  and	  Accreditation	  of	  Laboratory	  Animal	  Care	  International	  approved	  animal	  facility.	  They	  were	  kept	  4	  per	  plastic	  hanging	  cage	  (45	  ×	  24	  ×	  20	  cm).	  	  Colony	  rooms	  were	  maintained	  at	  23	   ±	   2°C	  with	   50	   ±	   10%	  humidity	   on	   a	   photoperiod	   of	   12L:12D	   (0600	   h–1800	   h).	   Food	  (Purina	   Rodent	   Chow	   #5001)	   and	   water	   were	   provided	   by	   the	   Institute.	   Tap	   water	  (Columbus,	   OH	   water)	   was	   centrally	   located	   in	   each	   cage.	   All	   animal	   procedures	   have	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already	  been	  approved	  by	  the	  Institutional	  Animal	  Care	  and	  Use	  Committee	  of	  the	  National	  Health	   and	   Environmental	   Effects	   Research	   Laboratory	   of	   the	   U.S.	   Environmental	  Protection	  Agency	  (U.S.	  EPA)	  for	  the	  research	  occurring	  in	  Dr.	  Gayle	  Gordillo’s	  laboratory	  in	  DHLRI.	  
Hemangioma	  Tumor	  Induction:	  	   From	  cell	   culture,	  20	  T75	  plates	  of	  EOMA	  cells	  were	  collected.	   	  Once	  washed	  with	  Phosphate	   Buffered	   Saline	   (PBS),	   they	   were	   centrifuged	   into	   a	   pellet.	   	   HBSS	   was	   used	  because	   it	   is	   a	   cell	   signaling	   buffer	   used	   to	   minimize	   cell	   death	   during	   cell	   transfer	  procedures.	  	  The	  pellet	  was	  diluted	  1:20.	  	  To	  count	  the	  cells,	  Trypan	  Blue	  Stain	  (0.4%)	  was	  used.	  	  Based	  on	  the	  number	  of	  cells	  in	  solution,	  a	  master	  solution	  of	  cells	  was	  created	  with	  a	  concentration	   of	   5	  million	   cells	   per	   100	   uL	   of	   PBS.	   	   20	   syringes	  were	   then	   prepared	   for	  injection,	   each	  with	   100	   uL	   containing	   PBS	   and	   5	  million	   EOMA	   cells.	   	   Each	  mouse	  was	  sedated	  under	  local	  anesthetic.	  	  The	  posterior	  of	  the	  mouse	  was	  shaved	  via	  electric	  trimmer	  and	  the	  skin	  prepared	  with	  Nair.	   	  The	  skin	  was	  washed	  with	  water	  and	  thoroughly	  dried.	  	  Cells	  were	  injected	  beneath	  a	  small	  patch	  of	  skin	  on	  the	  posterior	  of	  each	  mouse.	  	  Within	  3-­‐4	   days,	   the	   EOMA	   cells	   had	   connected	   with	   the	   vasculature	   of	   the	   host	   mouse	   and	   the	  tumor	  was	  visible	  by	  the	  naked	  eye.	  	  
PediaBerry™	  Application:	  
	   Each	   morning	   at	   11am	   the	   mice	   were	   treated	   with	   PediaBerry™	   ointment	   at	   the	  surface	  of	  the	  tumor.	  	  The	  tumor	  was	  then	  covered	  with	  a	  thin	  adhesive	  Tegaderm	  film	  to	  ensure	  the	  treatment	  was	  not	  removed	  after	  application.	  	  Every	  three	  days,	  the	  skin	  surface	  was	  shaved,	  prepared	  with	  Nair,	  and	  washed	  with	  water	  before	  application	  to	  ensure	  full	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contact	   and	   absorption	   of	   the	   ointment.	   	   The	   mice	   will	   not	   be	   sedated	   after	   the	   initial	  injection	  day,	  however,	  because	  receiving	  full	  anesthetics	  each	  day	  is	  unnatural	  and	  could	  become	   a	   confounding	   variable.	   Eight	   mice	   were	   treated	   daily	   with	   PediaBerry™	   while	  seven	   received	   a	   vehicle	   application	   (control	   group).	   	   The	   vehicle	   application	   was	   an	  application	  of	  all	  components	  except	  for	  the	  berry	  extracts,	  meaning	  that	  the	  control	  group	  received	   the	   cream	   in	  which	   the	   extracts	  were	   suspended,	   as	  well	   as	   the	  Tegaderm	   film.	  This	   experiment	  was	   capped	  at	   10	  days	  because	  of	   data	   from	  previous	   longevity	   studies	  showing	  that	  mice	  with	  untreated	  hemangioma	  tumors	  do	  not	  survive	  much	  past	  10	  days	  after	  injection	  (Gordillo,	  2009).	  	   An	   additional	   longevity	   experiment	   ran	   in	   a	   separate	   set	   of	  mice.	   	   Each	  morning,	  headcounts	  were	  taken	  in	  both	  treatment	  and	  control	  groups,	  creating	  a	  recording	  of	  each	  mouse’s	  lifespan.	  	  	  	  
Tumor	  Analysis:	  	   General	   tumor	   size	   after	   10	   days	   of	   treatment	   was	   compared	   with	   the	   starting	  tumor	  size	  on	  Day	  3	  (when	  tumors	  established	  a	  connection	  with	  the	  host	  and	  application	  began),	   and	   the	   same	  was	   done	   to	   the	   tumors	   of	   the	   control	   group.	   	   After	   collecting	   the	  tumors,	  success	  of	  treatment	  was	  measured	  via	  protein	  biomarkers.	  	  Proteins	  were	  tagged	  and	  processed	  via	   fluorescent	   imaging	  and	   included	  Ki-­‐67,	  a	  cell	  proliferation	  biomarker,	  Collagen-­‐1,	  which	  indicates	  tumor	  rigidity,	  and	  F4/80,	  a	  macrophage	  biomarker.	  DAPI	  was	  used	  as	  a	  standard	  cell	  nuclei	  indicator.	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Results:	  	  	   Survival	   rates	   for	  each	   group	   of	   mice	   were	  determined	   based	   on	   the	  headcounts	   taken	   each	  morning.	   As	   seen	   in	  
Figure	  2,	  the	  mice	  treated	  with	   PediaBerry™	  
survived	   significantly	   longer	   than	  those	   in	   the	   control	   group.	   	   At	   the	  point	  in	  time	  when	  100%	  (n=7)	  of	  the	  control	  group	  had	  expired,	  50%	  (n=4)	  of	   the	   treatment	  group	  was	  still	  alive.	  	  Some	   mice	   in	   the	   treatment	   group	  (n=2)	  lived	  over	  2	  times	  longer	  than	  the	  longest	  living	  mice	  in	  the	  control	  group	   (n=3).	   	   At	   the	   point	  when	   all	  of	  the	  mice	  in	  the	  control	  group	  had	  expired	   (n=7),	   75%	   (n=6)	   of	   the	  mice	  from	  the	  treatment	  group	  were	  still	  alive.	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   In	   this	   longevity	   study,	   pictures	  were	   captured	   of	   the	  mice	   as	   a	   visual	   display	   of	  macroscopic	  tumor	  display.	  	  As	  shown	  in	  Figure	  3,	  tumor	  size	  was	  recorded	  on	  Day	  3,	  the	  beginning	  of	  the	  experiment,	  and	  on	  Days	  7	  and	  12.	  	  For	  comparison,	  the	  mouse	  surviving	  the	   longest	   in	   the	   vehicle	   group	   is	   shown	   against	   a	   mouse	   whose	   treatment	   prolonged	  lifespan	  just	  short	  of	  three	  times	  that	  of	  the	  control	  group.	  	  The	  mouse	  in	  the	  vehicle	  group	  expired	  on	  Day	  13	  while	  the	  mouse	  treated	  with	  PediaBerry™	  expired	  on	  Day	  31.	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The	   second	   study	  performed	   in	   vitro	  was	   a	   comparative	   study	  where	   the	  mice	   in	  both	  groups	  were	  sacrificed	  at	  Day	  10.	  	  Captured	  here	  at	  Day	  3	  and	  Day	  10,	  Figure	  4	  shows	  the	  differences	  in	  tumor	  size	  from	  the	  first	  to	  the	  last	  day	  of	  study.	  	  The	  tumor	  treated	  with	  PediaBerry™	  did	  not	   increase	   in	  size	  and	   its	  size	  was	  rather	  well	  maintained.	   	  The	  tumor	  withheld	  from	  treatment	  formed	  two	  tumors	  which	  both	  grew	  significantly	  larger	  than	  the	  original	  tumor.	  	  	   	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  4:	  	  Initial	  and	  final	  tumor	  size	  comparisons	  show	  maintained	  tumors	  in	  PediaBerry™	  group	  (mice	  not	  photographed	  quantify	  the	  trend	  in	  this	  figure	  in	  Figure	  5)	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Each	   tumor	   was	   excised	   from	   the	   mouse	   and	   measured	  volumetrically.	   	  As	  shown	  in	  Figure	  5,	  mice	  in	  the	  treatment	  group	  (n=8)	   had	   significantly	   smaller	   tumors	   than	   mice	   whose	   tumors	  were	  left	  untreated	  (n=7).	  	  	  	   The	  tumors	  were	  further	  analyzed	  via	  fluorescent-­‐tag	  protein	   analysis.	   	  All	   tumors	  were	   cut	   to	   include	   the	  entire	   tumor	  as	  well	  as	   the	  section	  of	   the	  mouse’s	   tissue	  between	   the	   host	   organism	   and	   the	   tumor.	   	   With	   this	  methodology,	   the	   tumor	   sections	   enabled	   the	  determination	   of	   not	   only	   the	   content	   of	   the	   tumor	   but	  the	   transition	   from	   the	  mouse’s	   connective	   tissue	   to	   the	  tumor	  as	  well.	  	  The	  stains	  that	  were	  used	  were	  for	  Collagen-­‐1,	  F4/80,	  and	  Ki-­‐67.	  	  	  	  	  	  	  	  	  	  	  
Figure	  5:	  Decreased	  tumor	  size	  in	  mice	  treated	  with	  PediaBerry™	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Cryosections	  of	  the	  vehicle	  application	  and	  treatment	  applications	  were	  stained	  for	  Collagen-­‐1	  protein	  content,	  which	  is	   indicated	  by	  fluorescent	  green.	   	  Figure	  6	  shows	  that	  the	  vehicle	  group	  had	  much	  higher	  levels	  of	  collagen	  content	  than	  the	  group	  treated	  with	  PediaBerry™.	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Vehicle	  Application	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Treatment	  Application	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Tumors	  were	  also	  stained	  to	  show	  the	  protein	  F4/80,	  a	  biomarker	  for	  macrophages.	  	  In	  Figure	  7,	  macrophage	  content	   is	  compared	  between	  tumor	  sections	  of	  the	  vehicle	  and	  treatment	  application.	  	  Macrophage	  content	  appears	  similar	  in	  both	  groups.	   	  	  	  	  	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Vehicle	  Application	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Treatment	  Application	  	  	  	  	  	  	  	  	  	  	  	   	  	  	  	  	  	  	  	  	  	  	  	  
Figure	  7:	  	  Similar	  F4/80	  protein	  content	  shown	  with	  red	  fluorescence	  in	  tumor	  cryosections	  with	  magnified	  views	  outlined	  and	  shown	  beneath.	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Tumor	  sections	  were	  stained	  for	  Ki-­‐67,	  a	  cell	  proliferation	  protein	  marker.	  	  Figure	  8	  shows	  that	  in	  the	  control	  section,	  cell	  proliferation	  seems	  to	  take	  place	  only	  in	  the	  mouse’s	  connective	   tissue.	   	   The	   fluorescence	   in	   the	   control	   group	   is	   clear	   and	   bright.	   	   In	   the	  treatment	   group	   shown	   below,	   however,	   any	   significant	   Ki-­‐67	   concentration	   was	  eliminated.	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Vehicle	  Application	   	   	   	  	  	  	  Treatment	  Application	  	  	  	  	  	  	  	  	  	  	  	  	  	   	   	   	  	  	  	  	  	  	  	  	  	  	  
Figure	  8:	  	  Significant	  decrease	  in	  Ki-­‐67	  content	  shown	  in	  green	  fluorescence	  in	  the	  cryosections	  with	  magnified	  views	  outlined	  and	  shown	  below	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Analysis:	  	   The	  results	  of	  this	  study	  provide	  promising	  evidence	  and	  routes	  into	  further	  study.	  	  Through	  the	  longevity	  study	  on	  survival	  rates,	  the	  PediaBerry™	  ointment	  shows	  evidence	  of	   tumor	   suppression	   and	   prolonged	   lifespans.	   	   The	   experimentation	   on	   tumor	  biochemistry	   provides	   further	   evidence	   of	   the	   success	   of	   PediaBerry™	   ointment	   on	   a	  molecular	  level.	  	   In	   the	   first	   study	   conducted,	   mice	   were	   treated	   with	   PediaBerry™	   ointment	   and	  tested	  until	  expiration.	   	  As	  seen	   in	  Figure	  2,	   the	  mice	  treated	  with	  PediaBerry™	  ointment	  lived	  significantly	   longer	   than	   those	  untreated.	   	  Figure	  3	  depicts	   the	  visual	  differences	   in	  tumors	  between	   those	   treated	  with	  PediaBerry™	  and	   those	   left	  untreated.	   	   In	   this	   figure,	  the	   control	  mouse	   saw	   significant	   tumor	   growth	   in	   12	   days,	   followed	   by	   its	   death.	   	   The	  mouse	   treated	  with	   PediaBerry™,	   however,	  maintained	   the	   same	   tumor	   size	   from	  Day	   3	  until	   Day	   31.	   	   This	   data	   is	   promising	   evidence	   of	   the	   success	   of	   the	   ointment	   since	   the	  tumors	  were	  the	  same	  size	  at	  the	  beginning	  of	  the	  experiment	  and	  saw	  completely	  different	  paths,	  due	  to	  PediaBerry™.	   	  From	  this	  in	  vitro	  study,	  the	  ointment	  proves	  to	  work	  well	   in	  suppressing	   tumor	   growth	   and	   promoting	   survival	   of	   the	   organisms	   inflicted	   with	   this	  tumor.	   	   Additional	   support	   for	   the	   beneficial	   effects	   of	   PediaBerry™	   ointment	   was	  quantified	   in	   Figure	   5.	   	   This	   example	   shows	   the	   differences	   in	   overall	   tumor	   volume	  between	  the	  two	  groups.	  	  Clearly,	  tumors	  were	  smaller	  after	  PediaBerry™	  treatment.	  	  Since	  Figure	  5	  provides	  results	  on	  all	  of	   the	   tumors	  of	  each	  group,	   this	  depiction	  also	  supports	  the	   validity	   of	   the	   single	   mice	   chosen	   as	   representative	   mice	   in	   Figures	   3	   and	   4.	   	   The	  smaller	  tumors	  provide	  clear	  evidence	  to	  any	  observer	  that	  PediaBerry™	  works	  in	  reducing	  tumor	  size	  and	  proliferation.	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   Although	   PediaBerry™	   shows	   clear	   evidence	   on	   a	   macroscopic	   level,	   testing	   was	  done	   on	   the	   molecular	   level	   in	   order	   to	   gain	   a	   better	   understanding	   of	   the	   effects	   of	  PediaBerry™	  application.	   	  The	   two	  most	  promising	   stains	  were	   for	  Collagen-­‐1	  and	  Ki-­‐67.	  	  Collagen-­‐1,	   the	   fibrous	   protein	   found	   in	   rigid	   structures,	   is	   much	   higher	   in	   the	   tumors	  omitted	   from	   PediaBerry™	   treatment.	   	   As	   Figure	   6	   demonstrates,	   there	   is	   a	   drop	   in	  Collagen-­‐1	  content	  in	  the	  tumor	  sections	  of	  the	  treated	  tumors.	  	  These	  results	  support	  the	  data	  displayed	  in	  Figures	  3	  and	  4	  where	  smaller	  tumors	  were	  reported.	   	  Macroscopically,	  the	   tumors	  withheld	   from	   treatment	   grew	   in	   size,	  which	   explains	   the	   greater	   Collagen-­‐1	  content	   in	   the	  vehicle	  application	   tumor	  sections	   in	  Figure	  6.	   	  Lower	  Collagen-­‐1	   levels	   in	  tumors	  treated	  with	  PediaBerry™	  provides	  molecular	  data	   to	  support	   the	  smaller	   tumors	  seen	  in	  Figures	  3	  and	  4,	  moving	  towards	  the	  idea	  that	  the	  ointment	  plays	  a	  role	  in	  collagen	  content.	   	  These	  data	  provide	  context	  for	  an	  extension	  of	  this	  experiment	  in	  determining	  if	  PediaBerry™	   inhibits	   collagen	   deposition	   or	   if	   it	   degrades	   existing	   collagen,	   or	   perhaps	  both	   .	   	  Without	   collagen	   deposition,	   the	   tumor	   is	   unable	   to	   form	   a	   rigid	   tissue	   structure	  necessary	  for	  further	  growth.	  	  With	  collagen	  degradation,	  the	  tumor	  is	  unable	  to	  maintain	  a	  rigid	   structure,	   which	   would	   also	   inhibit	   proliferation.	   	   This	   stain	   on	   Collagen-­‐1	  demonstrates	  the	  positive	  effects	  of	  PediaBerry™	  on	  a	  molecular	  level.	  	  	  Ki-­‐67	  protein	  stains	   show	  even	  greater	   results	   for	   the	  success	  of	  PediaBerry™.	   	   In	  Figure	   8,	   the	   treated	   tumors	   show	   significant	   decreases	   in	   the	   cell	   proliferation	   protein	  biomarker	   compared	   to	   the	   sections	   of	   untreated	   tumors.	   	   In	   the	   control	   group,	   a	  significant	   amount	   of	   Ki-­‐67	   is	   found	   throughout	   the	   tumor	   section.	   	   This	   Ki-­‐67	   content,	  however,	  is	  almost	  eliminated	  entirely	  when	  the	  tumor	  is	  treated	  with	  PediaBerry™.	  	  Low	  levels	   of	   Ki-­‐67	   in	   the	   tumors	   treated	   with	   PediaBerry™	   show	   that	   cell	   proliferation	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decreases	  in	  the	  tumor	  treated	  with	  PediaBerry™.	   	  This	  molecular	  data	  is	  seen	  directly	   in	  Figure	  3	  as	  the	  treated	  tumor’s	  growth	  and	  expansion	  is	  stunted	  greatly	  compared	  to	  the	  tumor	   left	   untreated.	   	   This	   molecular	   data	   provides	   strong	   support	   for	   the	   viability	   of	  PediaBerry™.	  	   The	   same	   tumor	   sections	   were	   stained	   for	   F4/80,	   a	   macrophage	   biomarker,	   to	  visualize	  the	  activity	  of	  the	  immune	  system	  in	  combatting	  the	  tumor.	  	  The	  images	  in	  Figure	  7	  show	  no	  significant	  differences	   in	   the	  macrophage	  content	  between	  the	  treated	  tumors	  and	  those	  in	  the	  control	  group.	   	  However,	  the	  detail	  of	  the	  macrophage	  stain	  is	  important	  information	  left	  undiscovered	  by	  the	  F4/80	  stain.	  	  The	  origin	  (mouse	  or	  tumor),	  type,	  and	  exact	   roles	  of	   the	  macrophages	  are	  areas	   left	  uncharted	  by	   this	  work	   that	  would	  provide	  significant	  insight	  into	  the	  resulting	  macrophage	  content	  seen	  in	  Figure	  7.	  	  The	  Next	  Steps:	  	  	  	   The	   macrophage	   stains	   open	   the	   doors	   to	   a	   great	   expansion	   of	   the	   PediaBerry™	  treatment	   project.	   	   As	   seen	   in	   Figure	   7,	  macrophage	   content	   remained	   constant	  with	   or	  without	   treatment	  via	  PediaBerry™.	   	  As	   the	  groups	  receiving	  PediaBerry™	   treatment	  had	  much	   greater	   survival	   rates	   (Figure	   2),	   this	   prolonged	   lifespan	   could	   be	   attributed	   to	  undiscovered	  macrophage	  activity.	  	  With	  clear	  macrophage	  aggregation	  in	  both	  application	  groups,	  the	  mystery	  behind	  the	  type	  and	  role	  of	  the	  macrophages	  leads	  to	  the	  next	  viable	  approach	  for	  this	  experiment.	  	  Macrophages	  maintain	  the	  ability	  to	  transform	  between	  two	  types	  of	  phenotypes,	  which	  possess	  counterbalancing	  functions	  in	  tissues.	   	  M1	  phenotype	  macrophages	  function	  in	  the	  standard	  manner—they	  are	  activated	  in	  response	  to	  bacteria	  or	   xenobiotic	  materials	   and	  promote	   inflammation	   (Mills	   2012).	   	   A	   second	  phenotype	  of	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macrophages	  exists,	  however,	  which	  acts	  by	  changing	  phenotypes	  from	  a	  proinflammatory	  mediator	   profile	   to	   an	   immunosuppressive	   one.	   	   This	  M2	   phenotype	   has	   been	   shown	   to	  protect	   cells	   from	   apoptosis.	   	   M2	   macrophages	   act	   by	   withdrawing	   cytokine	   in	  macrophages	   that	   have	   phagocytized	   apoptotic	   cells	   (Weigert	   2006).	   	   The	   phenotypic	  expression	  of	  M1/M2	  down	  regulate	  each	  other,	  demonstrating	  the	  importance	  of	  adaptive	  immunity	   in	   a	   counterbalanced	   system	   (Mills	   2012).	   M2	   macrophage	   activity	   has	   been	  reported	  directly	  in	  endothelial	  cells	  (Reddy	  2002,	  Golpon	  2004),	  providing	  viability	  to	  the	  extension	   of	   this	   endothelial	   macrophage	   investigation.	   	   Applying	   this	   knowledge	   on	  macrophage	   phenotypic	   differentiation,	   further	   investigation	   can	   reveal	   the	   type	   of	  macrophage	  present	  in	  the	  F4/80	  stains	  of	  this	  study.	  	  Theorizing	  towards	  further	  projects,	  tumors	   could	   be	   injected	   with	   manipulated	   phagocytic	   target	   materials,	   such	   as	   with	  protein	  marker	   tabs,	  which	  will	   determine	   the	  phenotype	  of	   the	  macrophages.	   	  With	   the	  ability	  to	  manipulate	  or	  even	  harness	  macrophage	  activity,	  further	  experimentation	  could	  provide	  means	  for	  pharmacological	  control	  of	  immune	  response	  to	  disease,	  specifically	  the	  inflammatory	  response	  to	  the	  endothelial	  cell	  tumor	  Hemangioma.	  After	  finding	  a	  decrease	  in	  collagen	  in	  the	  tumors	  treated	  with	  PediaBerry™,	  further	  experimentation	  in	  this	  route	  could	  include	  focus	  on	  fibroblast	  content.	  	  Fibroblasts,	  being	  the	   cells	   that	   create	   and	   lay	   down	   collagen	  matrices,	   could	   lead	   to	   a	   further	   explanation	  into	  how	  PediaBerry™	  works	  on	  the	  tumors.	  	  The	  fibroblast	  specific	  protein	  1	  (FSP-­‐1)	  is	  a	  biomarker	  that	  could	  offer	  insight	  into	  the	  content	  and	  location	  of	  fibroblasts	  in	  the	  tumors	  (Strutz	  et	  al.	  1995).	  	  Ultimately,	  there	  is	  either	  a	  significant	  fibroblast	  population	  in	  the	  HE	  tumor	   cells,	   or	   an	   overactive	   fibroblast	   growth	   factor	   (FGF)	   present	   in	   the	   tumor	   cells	  which	  would	   lead	  to	  the	  deposition	  of	  collagen	  seen	   in	  this	  study.	   	  Some	  FGFs	  are	  potent	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angiogenic	   factors	   and	   can	   play	   a	   role	   in	   tumor	   growth	   and	   angiogenesis	   (Powers	   200).	  	  Research	  may	   be	   able	   to	   determine	   how	   PediaBerry™	   alters	   fibroblast	   and	   FGF	   activity.	  	  This	  data	  could	   then	  explain	   the	  collagen	  decrease	  seen	   in	   this	  study.	   	  Fibroblast	  activity	  may	   be	   altered	   by	   PediaBerry™	   application,	   or	   FGF	   activity	  may	   be	   altered	   significantly.	  	  PediaBerry™	  application	  may	  also	  support	  the	  degradation	  and	  relocation	  of	  collagen	  in	  the	  tumors.	  	  Overall,	  an	  investigation	  in	  the	  realm	  of	  fibroblast-­‐related	  activity	  is	  important	  in	  explaining	  the	  results	  found	  in	  Figure	  6.	  	  How	  and	  why	  is	  the	  collagen	  content	  decreased?	  	  The	   research	   gap	   in	   the	   PediaBerry™	   study	   regarding	   fibroblast	   activity	   is	   an	   important	  opportunity	  to	  build	  upon	  the	  collagen	  findings	  of	  this	  study.	  	   The	   final	   extension	   of	   the	   PediaBerry™	   project	   grows	   off	   of	   the	   antioxidant	  properties	  in	  the	  PediaBerry™	  ointment	  itself.	   	  The	  antioxidant	  properties	  in	  PediaBerry™	  ointment	   are	   found	   within	   the	   anthocyanins	   of	   the	   blueberries.	   	   In	   the	   PediaBerry™	  ointment	  used	  in	  this	  study,	  however,	  the	  antioxidant	  capacity	  is	  unknown,	  as	  the	  level	  of	  active	  anthocyanins	  was	  never	  measured.	   	  Anthocyanins	  are	  known	  to	  alleviate	  oxidative	  stress	  processes—the	  entire	  reason	  for	  berry	  utilization	  in	  the	  first	  place—placing	  a	  great	  importance	   on	   the	   simple	   measurement	   of	   anthocyanin	   levels	   in	   the	   ointment.	   	   An	  extension	   to	   this	   study	   would	   be	   a	   repetition	   study	   that	   compares	   different	   levels	   of	  anthocyanins	  in	  the	  PediaBerry™	  ointment.	  	  Additionally,	  anthocyanins	  have	  been	  found	  to	  have	  cytoprotective	  functions	  in	  downregulating	  inflammatory	  cytokines	  and	  suppressing	  cellular	   signaling	   pathways	   of	   inflammatory	   processes	   (Sodagari	   2015).	   	   This	   study	   on	  anthocyanin	   activity	   provides	   full-­‐circle	   support	   for	   the	   macrophage	   phenotype	  investigation.	   	  Specifically,	   this	  study	  provides	  support	   for	  a	  hypothesis	   that	  PediaBerry™	  ointment	  invokes	  the	  M2	  phenotype	  in	  macrophage	  content	  as	  it	  downregulates	  cytokines.	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As	   anthocyanins	   present	   significant	   areas	   for	   further	   research	   in	   antioxidant	   properties,	  flavonoids	   are	   also	   another	   compound	   present	   in	   berries,	   known	   to	   have	   similar	   redox	  effects	  (Bagachi	  2006,	  Roy	  2002).	   	  The	  impact	  of	  flavonoids	  are	  another	  mystery	  in	  berry	  extract	   research	   left	   unresolved.	   	   This	   extensive	   study	   done	   on	   PediaBerry™	   ointment	  provides	   the	   basis	   for	   multiple	   experiments	   to	   add	   onto	   developing	   an	   effective	  nutraceutical	  to	  combat	  the	  proliferation	  of	  hemangioma	  tumors.	  	   	  
Significance:	  	   Nutritional	  interventions	  for	  HE	  tumors	  are	  particularly	  appealing	  given	  the	  young	  age	   of	   the	   affected	   population	   and	   the	   absence	   of	   non-­‐invasive	   treatment	   options.	   Berry	  extracts	  represent	  a	  viable	   therapeutic	  approach.	  The	  successful	  execution	  of	   this	  project	  provides	   evidence	   of	   significantly	   smaller	   tumors	   and	   longer	   lifespans	   via	   PediaBerry™	  treatment.	  	  This	  study	  provides	  the	  link	  between	  a	  micronutrient	  found	  in	  berries	  and	  their	  ability	  to	  treat	  HE	  tumor	  pathology.	  	  This	  information	  is	  a	  key	  step	  in	  the	  development	  of	  a	  non-­‐invasive	   treatment	  option	   for	  HE	   tumors	   to	  prevent	  debilitating	  consequences	  of	  HE	  tumors	  and	  ultimately	  save	  lives.	  	  The	  success	  of	  this	  in	  vitro	  study	  has	  seen	  the	  final	  stages	  of	   animal	   trials	   and	   since	  has	  provided	  evidence	  of	   success.	   	   	   PediaBerry™	  ointment	  will	  soon	  be	  ready	  for	  clinical	  trials.	   	  Further	  research	  could	  produce	  a	  pharmacological	  agent	  that	   will	   provide	   non-­‐invasive	   nutraceutical	   therapy	   to	   individuals	   suffering	   from	  Hemangioma	  tumors	  all	  around	  the	  world.	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